Literature DB >> 2658055

Class II MHC molecules are specific receptors for staphylococcus enterotoxin A.

J A Mollick1, R G Cook, R R Rich.   

Abstract

T cell proliferation in response to stimulation with Staphylococcus enterotoxin A (SEA) requires accessory cells that express class II major histocompatibility complex (MHC) molecules. Murine fibroblasts transfected with genes encoding the alpha and beta subunits of HLA-DR, DQ, or DP were used to show that the proliferative response of purified human T cells to SEA is dependent on class II molecules but is not restricted by the haplotype of the responder. Binding of fluoresceinated SEA to class II transfectants and precipitation of class II heterodimers with SEA-Sepharose show that the proliferative response is a result of SEA binding to class II molecules. The binding is specific for class II molecules and is independent of class II allotype or isotype. The ability of SEA to bind class II molecules may be a general characteristic of this class of antigens, now called "superantigens".

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658055     DOI: 10.1126/science.2658055

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  83 in total

Review 1.  Superantigens: biology, immunology, and potential role in disease.

Authors:  C G Drake; B L Kotzin
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

2.  Relative abilities of distinct isotypes of human major histocompatibility complex class II molecules to bind streptococcal pyrogenic exotoxin types A and B.

Authors:  K Imanishi; H Igarashi; T Uchiyama
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

3.  Distinct T-cell receptor V beta gene usage by human T lymphocytes stimulated with the streptococcal pyrogenic exotoxins and pep M5 protein.

Authors:  M A Tomai; P M Schlievert; M Kotb
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

4.  Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins.

Authors:  M Dohlsten; P A Lando; G Hedlund; J Trowsdale; T Kalland
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

5.  The T cell receptor beta-chain second complementarity determining region loop (CDR2beta governs T cell activation and Vbeta specificity by bacterial superantigens.

Authors:  A K M Nur-ur Rahman; Daniel A Bonsor; Christine A Herfst; Fraser Pollard; Michael Peirce; Aaron W Wyatt; Katherine J Kasper; Joaquín Madrenas; Eric J Sundberg; John K McCormick
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

6.  Relative activities of distinct isotypes of murine and human major histocompatibility complex class II molecules in binding toxic shock syndrome toxin 1 and determination of CD antigens expressed on T cells generated upon stimulation by the toxin.

Authors:  T Uchiyama; S Saito; H Inoko; X J Yan; K Imanishi; M Araake; H Igarashi
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

7.  A highly sensitive in vitro infection assay to explore early stages of mouse mammary tumor virus infection.

Authors:  S Vacheron; T Renno; H Acha-Orbea
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

8.  Allelic polymorphisms at the H-2A and HLA-DQ loci influence the response of murine lymphocytes to the Mycoplasma arthritidis superantigen MAM.

Authors:  B C Cole; A D Sawitzke; E A Ahmed; C L Atkin; C S David
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

9.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).

Authors:  A Norrby-Teglund; D Newton; M Kotb; S E Holm; M Norgren
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Expression of the identical V beta gene in human T-cell clones does not confer the same pattern of responsiveness to bacterial enterotoxins.

Authors:  S Quaratino; A Verhoef; M Kahan; M Londei
Journal:  Immunology       Date:  1993-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.